Citigroup’s Altimmune ALT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $235K | Buy |
76,327
+48,003
| +169% | +$204K | ﹤0.01% | 3936 |
|
|
2025
Q4 | $102K | Buy |
28,324
+18,550
| +190% | +$80.9K | ﹤0.01% | 4320 |
|
|
2025
Q3 | $36.8K | Sell |
9,774
-58,407
| -86% | -$226K | ﹤0.01% | 4590 |
|
|
2025
Q2 | $264K | Sell |
68,181
-95,337
| -58% | -$516K | ﹤0.01% | 3935 |
|
|
2025
Q1 | $818K | Buy |
163,518
+38,828
| +31% | +$246K | ﹤0.01% | 3387 |
|
|
2024
Q4 | $899K | Buy |
124,690
+72,875
| +141% | +$557K | ﹤0.01% | 3441 |
|
|
2024
Q3 | $318K | Buy |
51,815
+15,430
| +42% | +$105K | ﹤0.01% | 4036 |
|
|
2024
Q2 | $242K | Sell |
36,385
-706,528
| -95% | -$5.21M | ﹤0.01% | 3792 |
|
|
2024
Q1 | $7.56M | Buy |
742,913
+735,336
| +9,705% | +$7.48M | 0.01% | 1442 |
|
|
2023
Q4 | $85.2K | Buy |
7,577
+2,912
| +62% | +$12.2K | ﹤0.01% | 4264 |
|
|
2023
Q3 | $12.1K | Sell |
4,665
-11,024
| -70% | -$31.6K | ﹤0.01% | 4503 |
|
|
2023
Q2 | $55.4K | Sell |
15,689
-396,861
| -96% | -$1.78M | ﹤0.01% | 4588 |
|
|
2023
Q1 | $1.74M | Buy |
412,550
+120,745
| +41% | +$1.43M | ﹤0.01% | 2112 |
|
|
2022
Q4 | $4.8M | Buy |
291,805
+19,699
| +7% | +$221K | ﹤0.01% | 1489 |
|
|
2022
Q3 | $3.48M | Sell |
272,106
-617,364
| -69% | -$9.12M | ﹤0.01% | 1764 |
|
|
2022
Q2 | $10.4M | Buy |
889,470
+99,343
| +13% | +$613K | 0.01% | 1139 |
|
|
2022
Q1 | $4.81M | Sell |
790,127
-276,268
| -26% | -$2.03M | ﹤0.01% | 1696 |
|
|
2021
Q4 | $9.77M | Buy |
1,066,395
+957,330
| +878% | +$10.2M | 0.01% | 1394 |
|
|
2021
Q3 | $1.23M | Sell |
109,065
-166,894
| -60% | -$2.03M | ﹤0.01% | 2927 |
|
|
2021
Q2 | $2.72M | Buy |
275,959
+16,064
| +6% | +$220K | ﹤0.01% | 2412 |
|
|
2021
Q1 | $3.67M | Buy |
259,895
+242,535
| +1,397% | +$3.92M | ﹤0.01% | 2036 |
|
|
2020
Q4 | $196K | Buy |
17,360
+17,060
| +5,687% | +$201K | ﹤0.01% | 5007 |
|
|
2020
Q3 | $4K | Sell |
300
-21,315
| -99% | -$426K | ﹤0.01% | 7090 |
|
|
2020
Q2 | $231K | Buy |
+21,615
| New | +$119K | ﹤0.01% | 4905 |
|
|
2017
Q2 | – | Sell |
-1
| Closed | – | – | 7326 |
|
|
2017
Q1 | $0 | Sell |
1
-711
| -100% | -$380K | ﹤0.01% | 7170 |
|
|
2016
Q4 | $694K | Buy |
712
+695
| +4,088% | +$623K | ﹤0.01% | 4043 |
|
|
2016
Q3 | $15K | Sell |
17
-4
| -19% | -$3.14K | ﹤0.01% | 6347 |
|
|
2016
Q2 | $15K | Buy |
21
+18
| +600% | +$12.3K | ﹤0.01% | 6306 |
|
|
2016
Q1 | $2K | Sell |
3
-1
| -25% | -$512 | ﹤0.01% | 7186 |
|
|
2015
Q4 | $2K | Sell |
4
-3
| -43% | -$1.5K | ﹤0.01% | 7247 |
|
|
2015
Q3 | $3K | Hold |
7
| – | – | ﹤0.01% | 6891 |
|
|
2015
Q2 | $4K | Hold |
7
| – | – | ﹤0.01% | 6837 |
|
|
2015
Q1 | $3K | Hold |
7
| – | – | ﹤0.01% | 6848 |
|
|
2014
Q4 | $4K | Sell |
7
-5
| -42% | -$2.57K | ﹤0.01% | 6713 |
|
|
2014
Q3 | $6K | Hold |
12
| – | – | ﹤0.01% | 6473 |
|
|
2014
Q2 | $5K | Sell |
12
-6
| -33% | -$2.71K | ﹤0.01% | 6440 |
|
|
2014
Q1 | $10K | Buy |
18
+4
| +29% | +$2.34K | ﹤0.01% | 6328 |
|
|
2013
Q4 | $8K | Sell |
14
-3
| -18% | -$1.79K | ﹤0.01% | 6472 |
|
|
2013
Q3 | $11K | Buy |
17
+3
| +21% | +$1.72K | ﹤0.01% | 6163 |
|
|
2013
Q2 | $7K | Buy |
+14
| New | +$6.94K | ﹤0.01% | 6221 |
|
Other funds holding ALT
VCM
VPM
N
Citigroup's ALT Position: Q1 2026 in Review
Citigroup increased its Altimmune (ALT) stake by 169% in Q1 2026, buying an estimated $204K and bringing the position to 76,327 shares worth $235K. The position accounts for ﹤0.01% of the portfolio, ranked #3936.
Citigroup first reported a position in ALT in Q2 2013 and has held it in 40 quarters since. The position peaked at $10.4M in Q2 2022. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.
- Citigroup held 76,327 shares of Altimmune worth $235K as of Q1 2026.
- Citigroup bought 48,003 Altimmune shares in Q1 2026, an estimated $204K.
- Altimmune made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3936 holding.
- Citigroup first reported a position in Altimmune in Q2 2013 and has held it in 40 quarters since.
- Citigroup's Altimmune position peaked at $10.4M in Q2 2022.
- 173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.